Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment

Journal of Infection

Volumn 58, Issue 3, 2009, Pages 197-204

  Kobashi, Yoshihiro ^a   Mouri, Keiji ^a   Yagi, Shinichi ^a   Obase, Yasushi ^a   Miyashita, Naoyuki ^a   Oka, Mikio ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Active TB disease; Antituberculous treatment; IFN assay

Indexed keywords

CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; LEVOFLOXACIN; MYCOBACTERIUM ANTIGEN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BCG VACCINATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LARYNGEAL TUBERCULOSIS; LIVER DYSFUNCTION; LUNG TUBERCULOSIS; MALE; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL NEUROPATHY; SPUTUM SMEAR; T LYMPHOCYTE; TUBERCULOMA; TUBERCULOUS PERITONITIS; TUBERCULOUS PLEURISY;

AGED; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG MONITORING; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 61349169062     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.08.009     Document Type: Article

References (27)

1. Andersen P., Munk M.E., Pollock J.M., and Doherty T.M. Specific immune-based diagnosis of tuberculosis. Lancet 356 (2000) 1048-1049
2. Lalvani A., Pathan A.A., McShane H., Wilkinson R.J., Latif M., Conlon C.P., et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 163 (2001) 824-828
3. Pai M., Riley L.W., and Colford J.M. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 4 (2004) 761-776
4. Mazurek G.H., Jereb J., Lobue P., Iademarco M.F., Metchock B., and Vernon A. Division of tuberculosis elimination, national center for HIV, STD, and TB prevention, centers for disease control and prevention. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (2005) 49-55
5. Rothel J.S., and Andersen P. Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent?. Expert Rev Anti Infect Ther 3 (2005) 981-993
6. Pai M., Joshi R., Dogra S., Mendiratta D.K., Narang P., Kalantri S., et al. Serial testing of health care workers for tuberculosis using interferon-γ assay. Am J Respir Crit Care Med 174 (2006) 349-355
7. Chee C.B.E., KhinMar K.W., Gan S.H., Barkham T.M.S., Pushparani M., and Wang Y.T. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 175 (2007) 282-287
8. Pai M., Joshi R., Bandyopadhyay M., Narang P., Dogra S., Taksande B., et al. Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment. Infection 35 (2007) 98-103
9. Dheda K., Pooran A., Pai M., Miller R.F., Lesley K., Booth H.L., et al. Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results. J Infect 55 (2007) 169-173
10. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161 (2000) S221-S247
11. National Collaborating Center for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control (2006), Royal College of Physicians, London, UK
12. Mori T., Sakatani M., Yamagishi F., Takashima T., Kawabe Y., Nagao K., et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 170 (2004) 59-64
13. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 174 (2006) 736-742
14. Pathan A.A., Wilkinson K.A., Klenerman P., McShane H., Davidson R.N., Pasvol G., et al. Direct ex vivo analysis of antigen-specific IFN-γ-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: association with clinical disease state and effect of treatment. J Immunol 167 (2001) 5217-5225
15. Lalvani A., Nagvenkar P., Udwadia Z., Pathan A.A., Wilkinson K.A., Shastri J.S., et al. Enumeration of T cells specific for RD 1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 183 (2001) 469-477
16. Carrara S., Vincenti D., Petrosillo N., Amicosante M., Girardi E., and Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 38 (2004) 754-756
17. Nicol M.P., Pienaar D., Wood K., Eley B., Wilkinson R.J., Henderson H., et al. Enzyme-linked immunospot assay responses to early secretory antigenic target 6, culture filtrate protein 10, and purified protein derivative among children with tuberculosis: implication for diagnosis and monitoring of therapy. Clin Infect Dis 40 (2005) 1301-1308
18. Aiken A.M., Hill P.C., Fox A., McAdam K.P., Jackson-Sillah D., Lugos M.D., et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 6 (2006) 66
19. Kobashi Y., Obase Y., Fukuda M., Yoshida K., Miyashita N., and Oka M. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis 43 (2006) 1540-1546
20. American Thoracic Society. Centers for disease control and prevention; infectious diseases society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 167 (2003) 603-662
21. Berther F.X., Rasmussen P.B., Rosenkrands I., Andersen P., and Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 144 (1998) 3195-3203
22. Renshaw P.S., Panagiotidou P., Whelan A., Gordon S.V., Hewinson R.G., Williamson R.A., et al. Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6/CFP-10 complex. J Biol Chem 277 (2002) 21598-21603
23. Ferrand R.A., Bothamley G.H., Whelan A., and Dockrell H.M. Interferon-gamma responses to ESAT-6 in tuberculosis patients early into and after anti-tuberculosis treatment. Int J Tuberc Lung Dis 9 (2005) 1034-1039
24. Ulrichs T., Anding P., Kaufmann S.H.E., and Munk M.E. Numbers of IFN-γ-producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy. Int J Tuberc Lung Dis 4 (2000) 1181-1183
25. Wu-Hsieh B.A., Chen C.K., Chang J.H., Lai S.Y., Wu C.H., Cheng W.E., et al. Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. Clin Infect Dis 33 (2001) 1336-1340
26. Olsen A.W., Hansen P.R., Holm A., and Andersen P. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 30 (2000) 1724-1732
27. Veerapathran A., Joshi R., Goswami K., Dogra S., Moodie E.E., Reddy M.V., et al. T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PLoS ONE 26 (2008) e1850